Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines

V. Cecchinato, E. Erba, A. Basile, B. Scarpati, C. Fazi, B. Brando, P. Comi, R. Chiaramonte

Research output: Contribution to journalArticlepeer-review


T acute lymphoblastic leukemia cell lines treated with hexamethylene bisacetamide (HMBA) undergo a delay in cell cycle progression and increase susceptibility to apoptosis, although they never overcome the differentiation block. In accordance with changes in cell cycle and apoptosis, transitory p53 pathway activation commonly occurs. Bcl-2 inhibition further favours the pro-apoptotic effect of HMBA. Notch1 expression is down regulated by reduction of its transcription level. Accordingly, Notch1 protein and transcriptional activity were affected. Even if HMBA generally reduces Notch1 level in T acute lymphoblastic leukemia (T-ALL) cell lines, this does not commonly influence the biological response; in fact all the analysed cell lines, except CEM cells, display no biological effect following DAPT-induced Notch inhibition.

Original languageEnglish
Pages (from-to)791-797
Number of pages7
JournalLeukemia Research
Issue number5
Publication statusPublished - May 2008


  • Apoptosis
  • Bax
  • Bcl-2
  • Cell cycle
  • HMBA
  • Notch1
  • p53
  • T-ALL

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines'. Together they form a unique fingerprint.

Cite this